Market Overview

Needham Initiates Medtronic At Buy

Related MDT
Insulet's CEO Lets His Money Do The Talking
SkyTides: Insulet's President Provided 'Critical Misinformation To Investors'
Defense Sector Update November 28-December 4: Here Comes Huntington (Seeking Alpha)

Analysts at Needham initiated coverage on shares of Medtronic (NYSE: MDT) with a Buy rating.

The target price for Medtronic is set to $74.

Medtronic shares have climbed 16.85% over the past 52 weeks, while the S&P 500 index has jumped 16.68% in the same period.

Medtronic's shares fell 1.26% to close at $62.54 yesterday.

Latest Ratings for MDT

Nov 2016BarclaysMaintainsOverweight
Nov 2016BMO CapitalMaintainsOutperform
Nov 2016JefferiesMaintainsBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: NeedhamInitiation Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!